AI assistant
PFIZER INC — Board/Management Information 2026
Jun 18, 2026
29831_rns_2026-06-18_fe6c69ed-2fe9-4024-a9fc-446939dc9c43.zip
Board/Management Information
Open in viewerOpens in your device viewer
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): June 18, 2026
PFIZER INC .
(Exact name of registrant as specified in its charter)
| Delaware | 1-3619 | 13-5315170 |
|---|---|---|
| (State or other | (Commission File | (I.R.S. Employer |
| jurisdiction of | Number) | Identification No.) |
| incorporation) |
| 66 Hudson Boulevard East | 10001-2192 | |
|---|---|---|
| New York, | New York | (Zip Code) |
(Address of principal executive offices)
Registrant’s telephone number, including area code:
( 212 ) 733-2323
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
| Securities registered pursuant to Section 12(b) of the Act: — Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, $0.05 par value | PFE | New York Stock Exchange |
| 1.000% Notes due 2027 | PFE/27 | New York Stock Exchange |
| 2.875% Notes due 2029 | PFE/29 | New York Stock Exchange |
| 3.250% Notes due 2032 | PFE/32 | New York Stock Exchange |
| 3.875% Notes due 2037 | PFE/37A | New York Stock Exchange |
| 4.250% Notes due 2045 | PFE/45 | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.02 |
|---|
| On June 16, 2026, Dave Denton notified Pfizer Inc. (the “Company”) that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company’s financial or operating results or to any disagreements with the Company regarding the Company’s financial, operational, accounting or reporting policies or practices. In connection with Mr. Denton’s departure, the Company announced that Cecile Guegan, the Company’s Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026, while the Company conducts a comprehensive process to identify Mr. Denton’s successor. Ms. Guegan, 55, joined Pfizer in 2005 and has served in her current role since 2022. Previously, Ms. Guegan served in various leadership roles within Pfizer’s finance organization, including as Vice President, Finance, Research & Development and Business Office from 2020 to 2022. A copy of the Company’s press release announcing Mr. Denton’s departure and Ms. Guegan’s interim appointment is attached hereto as Exhibit 99.1 and is incorporated by reference herin. |
Item 9.01 Financial Statements and Exhibits
| (d) Exhibits | |
|---|---|
| Exhibit Number | Exhibit Description |
| 99.1 | Press Release of Pfizer Inc. dated June 18, 2026 |
| 104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| /s/ Margaret M. Madden |
|---|
| Margaret M. Madden |
| Senior Vice President and Corporate Secretary |
| Chief Governance Counsel |